In the clinical setting, the potential future for autophagy therapeutics lies in their combination with other targeted drugs, such as KRAS cascade inhibitors, specifically for well-defined molecular subtypes of pancreatic cancer that exhibit dependency on autophagy. This envisioned combination therapy approach would maximize the therapeutic impact by simultaneously targeting multiple key pathways involved in pancreatic cancer development and progression. Furthermore, in addition to the speculative perspective, the direct targeting of p53 activation holds promise in unlocking the full benefits of autophagy inhibition in the context of pancreatic cancer. However, further research and clinical studies are required to fully elucidate the synergistic effects and therapeutic potential of combining autophagy inhibition with p53 activation or other targeted therapies in pancreatic cancer.